Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Johnson & Johnson posts strong Q2 2026 with 6.6% revenue growth; rating downgraded to Buy on valuation.

JNJ

$271.49

+$1.25 +0.46%

Johnson & Johnson posts strong Q2 2026 with 6.6% revenue growth; rating downgraded to Buy on valuation.

Company Fundamentals

15 Jul 2026

Seeking Alpha

View Source

Bullish

Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a blue-chip stock. Despite continued operational strength and stable dividends above 2%, the analyst downgraded JNJ from Strong Buy to Buy due to valuation normalization and more cautious future share price expectations. JNJ remains a reliable long-term investment in the pharmaceutical sector.

More News (JNJ)

JNJ raises 2026 outlook after 6.6% Q2 sales growth led by DARZALEX and TREMFYA

Johnson & Johnson (JNJ) reported a 6.6% revenue increase to $25.3 billion in Q2 2026, driven by strong sales of key drugs DARZALEX and TREMFYA. The company raised its full-year 2026 guidance, supported by pipeline advancements including CAPLYTA's lab...

Analyst Insights

Bullish

1 day ago